Tag: POLARIX
FDA Approves Polatuzumab Vedotin Combination With R-CHP for People With Certain...
The U.S. Food and Drug Administration (FDA) has approved polatuzumab vedotin-piiq Polivy®; Genentech/Roche)* in combination with rituximab (Rituxan®; Genetech/Biogen), cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of two or greater.
Polatuzumab Vedotin in the Treatment of Patients with Previously Untreated Diffuse...
Diffuse large B-cell lymphoma (DLBCL), the most common type of an aggressive form of non-Hodgkin lymphoma (NHL) in the United States and worldwide, is...
